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Abstract
DNA replication has a finite measurable error rate, net of repair, in all cells. Clonal proliferation of cancer cells leads therefore
to accumulation of random mutations. A proportion of these mutational events can create new immunogenic epitopes that,
if processed and presented by an MHC allele, may be recognized by the adaptive immune system. Here, we use probability
theory to analyze the mutational and epitope composition of a tumor mass in successive division cycles and create a double
Po ¨lya model for calculating the number of truly tumor-specific MHC I epitopes in a human tumor. We deduce that
depending upon tumor size, the degree of genomic instability and the degree of death within a tumor, human tumors have
several tens to low hundreds of new, truly tumor-specific epitopes. Parenthetically, cancer stem cells, due to the asymmetry
in their proliferative properties, shall harbor significantly fewer mutations, and therefore significantly fewer immunogenic
epitopes. As the overwhelming majority of the mutations in cancer cells are unrelated to malignancy, the mutation-
generated epitopes shall be specific for each individual tumor, and constitute the antigenic fingerprint of each tumor. These
calculations highlight the benefits for personalization of immunotherapy of human cancer, and in view of the substantial
pre-existing antigenic repertoire of tumors, emphasize the enormous potential of therapies that modulate the anti-cancer
immune response by liberating it from inhibitory influences.
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Introduction
DNA replication is arguably central to life, and it occurs with
less than complete fidelity. The imperfection in fidelity leads to a
measurable error rate, net of repair, that is an essential and
inalienable component of any cell division, bacterial or mamma-
lian, normal or malignant. The estimates of the spontaneous
mutation rate vary from 10
25 to 10
29 per nucleotide per cell cycle,
depending upon the experimental system used [1]; much higher
rates obtain in case of cells with genetic instability [2,3] either
because of deficient DNA repair [4], or chromosomal instability
[5]. The mutations create the substratum for natural selection and
origin of species and malignant cancers alike. Prior mathematical
models for studying the role of genomic instability in tumorigenesis
[6] have relied upon simple compounding models of growth to
estimate the total number of mutations in a fully grown tumor.
We demonstrate here that such mutations can be effectively
captured using a double Po ¨lya urn scheme, and that doing so
allows us the mathematical flexibility to answer important
biological questions. Specifically, we address a facet of the
mutational repertoire of cancers, that has not received mathemat-
ical attention, i.e. the immunological consequences of the
mutational burden of tumors. One of us has previously suggested
that the mutational burden of tumors must inevitably lead to
generation of tumor-specific neo-antigens that must be unique for
each individual tumor because of randomness of the mutational
process [7]. However, no attempt at quantitative modeling of this
important phenomenon has been made by us or others. This is
largely due to two factors: the rules of immunological recognition,
specifically, the recognition of a complex of MHC I with stretches
of amino acids by CD8+ T lymphocytes, are considerably more
intricate, and hence less amenable to modeling than the binary
rules of mutations. Secondly, these rules have become clear only
during the last 10–15 years [8,9,10]. The results of our analyses
reveal that the tumor-specific repertoire of antigens is vast and
individually unique. Indeed, this conclusion was inherent in the
earliest experiments that pointed to the specific immunogenicity of
tumors (see [11] for review). These early studies, carried out with
transplantable but syngeneic tumors showed two distinct phenom-
ena: (i) each tumor could be used to immunize mice (or rats) and
the immunized animals were resistant to subsequent tumor
challenge with the immunizing tumor; (ii) the tumor reistance
was restricted to the tumor that was used to immunize. Mice
immunized to one tumor and resistant to it were still sensitive to
challenge with another tumor, even if the othe other tumor was of
the same histological origin, was induced in the same strain of
mice and by the same carcinogen, as the immunizing tumor. A
rigorous scrutiny of these phenomena using a large panel of
chemically induced tumors [12] still upheld the observations of
individually-specific immunogenicity of tumors initially made with
smaller numbers of tumors. As argued previously [7], these results
could be explained on basis of an antigen repertiore generated by
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form to that argument, raise a number of testable questions and
predictions and suggest novel avenues of immunotherapy of
human cancer.
Results
The basic model of mutational burden of a tumor
A very small number of admittedly simplistic assumptions are
used to create a basic model into which more realistic components
may be incorporated. The assumptions are: (a) A cancer is clonal
in origin. (b) The mutation rate in the cancer is invariant through
the cancer’s lifetime. Genetic instability including repair deficien-
cies and chromosomal instability, are not modeled in the basic
model, but have been incorporated in its variants. (c) Cancer cells
die at an invariant rate through the cancer’s life time. Selected
variations in death rates during a tumor’s evolution may be added
to the basic model. (d) The mutations are all point mutations, and
no reversions occur. This is perhaps the most simplistic of all
assumptions. The mutational complexity of tumors including
deletions and insertions is fully acknowledged, but not represented
in our models. (e) All mutations are ‘equal’ such that no mutation
confers a survival advantage or disadvantage to the cell harboring
it. This clearly incorrect assumption is made because an
overwhelming majority of mutations indeed are ‘equal’ and are
incidental to survival or malignant transformation. In light of these
simplifications, our model represents a minimal representation of
tumor-associated genetic changes.
The classical formulation of Po ¨lya’s urn problem can be stated
as follows: an urn initially contains r red and b blue marbles. One
marble is chosen randomly from the urn. The marble is then put
back into the urn together with c more marbles (presumably from a
collection stored elsewhere) of the same color. Results computing
the probability of the existence of k red marbles in the urn after t
trials are well-known.
If we model the reproduction of each individual base pair in this
setting, it is immediately evident that c=0 in this case, since the
size of the genome remains constant. Hence, we get a binomial
distribution over the number of mutations in a cell cycle. This may
be represented as,
Pr n;k;p ðÞ ~
n
k
  
pk 1{p ðÞ
n{k ð1Þ
where n is the number of base pairs, p is the probability of faulty
reproduction of a single base pair, and k is the number of
mutations in the entire DNA sequence in the daughter cells.
Now, we must derive an updated equation for the change in the
number of mutations across cell cycles, where the number of
mutations produced in each cycle follow the same generative
model as shown in Eqn. (1). In that case, we can compute the
probability of the existence of k2 mutations, given the existence of
k1 mutations k2§k1 ðÞ in the previous cell cycle as
Pr k2 ðÞ ~Pr k1 ðÞ |Pr k2{k1 ðÞ
Thus, recursively, it follows that the probability of seeing k
mutations in the Tth cell cycle will be
PrT k ðÞ ~
X k
i~0
Pr i ðÞ |PrT{1 k{i ðÞ ð 2Þ
Alternatively, we can derive an analytical expression for PrT k ðÞ if
we assume that mutation of an already mutated base pair is
statistically irrelevant. This is a completely justifiable assumption,
and allows us to calculate the probability ~ p p that a single base pair
will mutate across a series of T cycles as,
~ p p~1{ k ðÞ
T: ð3Þ
Using p~~ p p in Eqn (1), we will obtain the probability of the
existence of k mutations in the Tth cell cycle as,
PrT k ðÞ ~
n
k
 !
1{ 1{p ðÞ
T
hi k
1{ 1{ 1{p ðÞ
T
hi    n{k
~
n
k
 !
1{p ðÞ
Tn {k ðÞ 1{ 1{p ðÞ
T
hi k
ð4Þ
In light ofthecalculations described above,startingwith a diploid
human genome of 6610
9 bp, and assuming a conservative
spontaneous mutation rate of 5610
29/bp/cell cycle, the average
number of mutations generated in each cell cycleis simply the mean
of the binomial distribution in Eqn. (1) and is calculated as 30.
Next we consider the average number of mutations per cancer
cell in a tumor of size 1 cm
3 or approximately 10
9 cells. A cancer
cell would have to undergo approximately 30 cycles to arrive at
that size. As each daughter cell would retain the mutations that it
inherits from its parent, the average cumulative number of
mutations per cell at the end of 30 cycles, shall be 900. With
increasing number of cycles, and increasing tumor mass, an
increasing number of mutations will accumulate linearly per cell
Fig. 1(a). The actual distribution of mutational complexity follows
the probability density defined in Eqn. (4) and is visualized in
Fig. 1(b). As each cycle shall generate random mutations anew, the
various cells in the tumor shall not have a homogeneous
composition, but shall be mosaics of overlapping compositions.
Altogether, this tumor of 10
9 cells shall harbor ,9610
11
mutations. If we assume that mutations that occur in less than
10% of the total cells in the tumor are undetectable in the
laboratory, mutations that occur after the fourth cell cycle will be
undetectable. Therefore, the actual number of mutations that we
would expect to find in a tumor of size 1 cm
3 under experimental
conditions will be about 1.2610
11.
Should one assume the presence of a mutator mutation in the
parental cancer cell that enhances the mutation rate one hundred
fold, one similarly arrives at a number of 90,000 mutations per cell
by the time the tumor achieves a size of 10
9 cells. Under these
conditions, one out of every 60,000 bp shall have undergone a
mutation.
Death rate and the number of mutations
In the scenario envisioned in the previous section, thirty cycles
shall be achieved within a month, assuming no stasis or cell death.
While situations of invariant cell death rates must arise
occasionally in course of evolution of human tumors, it is an
unlikely scenario during genesis of a tumor. A new developing
tumor, or a newly metastatic lesion undergoes successive cycles of
vigorous expansion and cell death depending upon whether or not
it is vascularized, the extent of immunological attack it encounters,
in addition to other inchoate factors. This scenario cannot be
modeled with any degree of accuracy. One can however consider
an invariant and uniform death rate d~1{w, where w is the
Human Tumor-Specific Epitopes
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calculate the number of cell cycles required for the tumor to attain
a certain size N using,
T~
logN
log 2{d ðÞ
, ð5Þ
and use this value of T in Eqn. (4) to estimate the number of
mutations in the cell population. The higher the death rate, the
more cycles a cell would have undergone before achieving a
certain size Fig. 2(a). As more cycles inevitably involve more
mutations, a tumor with a higher death rate would have a larger
number and larger complexity of mutations than a tumor with a
lower death rate Fig. 2(b).
Revising our estimates to account for a steady and random
death rate, we work with a reasonable assumption that it takes 300
cycles (about ten months) for a tumor to grow from a cell to a size
of 1 cm
3 which is ,10
9 cells. In this case, the expected number of
mutations in the grown tumor will multiply ten-fold from the
previous figure of 900 mutations to 9000 mutations per cell.
Calculating the number of experimentally observable mutations
will follow a somewhat different route in this case. We will have to
assume that mutations that occur after the tumor has reached 10%
of its final size will not be detectable. We will now have d&0:9285,
which implies that mutations that occur after T&115 will not be
detectable. Thus, we get an expected value of 3450 experimentally
detectable mutations per cell in a tumor of about 1 cm
3 or ,10
9
cells, assuming a mutation rate of 5610
29/bp/cell cycle and a
modest death rate. This calculation is valid for tumors of the same
size; number of mutations will be proportionately higher in larger
tumors, or tumors with higher rates of mutations and higher rates
of cell death.
From mutational content to definition of the tumor
immunome
Starting with the deduction that a tumor of 10
9 cells harbors an
average of 9000 mutations per cell (over 300 cell cycles), and with
the assumption that mutations are distributed randomly between
the coding and non-coding segments of the genome, one can
calculate the number of mutations in the coding genome, at 1.5%
or 135 per cell. Calculating that one third of these mutations shall
fall on each of the three positions of a triplet codon, and further
that mutations in the first and second positions shall be productive,
and those in the third position, silent, one arrives at a number of
90 alterations in the coding sequences of this tumor cell. How
many new antigenic epitopes do these alterations create?
In order to model this, we have chosen to focus on the epitopes
that can be potentially processed and charged onto MHC I
molecules and potentially recognized by CD8+ T lymphocytes.
While other aspects of the immune system play important roles in
immunological resistance to cancer, the MHC I -restricted,
antigen-specific response plays a central role. In order to
determine the number of MHC I epitopes that shall be generated
by the 90 productive mutations per cell, we wanted to identify the
possible number of sites in the coding genome which were one
amino acid ‘short’ of a consensus HLA I motif, and which
therefore could be converted into a perfect motif by a single point
mutation. However, no such super-motif exists. We have
approached the problem by narrowing our calculations to HLA
A2, one of the more common allele and one for which a well-
defined motif - (a 9-mer peptide with small and aliphatic residues
ATSVLIMQ in the B pocket and aliphatic and small hydrophobic
residues ALIVMQ in the F pocket) -exists [9].
To compute the number of HLA A2 alleles that will arise as a
consequence of random mutations, we follow a simple line of
probabilistic argument, outlined below,
1. We have calculated that the average number of productive
mutations in the coding region of the genome of a tumor of a
cell mass of 10
9 cells is about 90/cell.
2. The coding region of the genome is taken to comprise of about
1.5% of the total sequence ,9610
7 base pairs, translated to
,3610
7 [13].
3. Since 9-mers can overlap, the total number of possible 9-mers
can also be taken to be ,3610
7.
4. Recall that A2 motifs are characterized by the combined
presence of one of 8 residues in the B pocket and one of 6
Figure 1. Modeling the numbers of accumulating mutations in dividing cells using a probabilistic model. (a) Prediction of average
number of accumulated mutations per diploid human cell as a function of numbers of cell cycles. The model assumes a diploid DNA content of
6610
9 bp and a number of possible mutation rates (10
29,5610
29,10
28,5610
28 per bp per cell cycle) as indicated. (b) The numerical profile of
mutations in a clonally derived cell population of approximately 10
9 cells (after 30 division cycles). A spontaneous mutation rate of 5610
29 is
assumed.
doi:10.1371/journal.pone.0006094.g001
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HLA A2 motifs in the coding region, we therefore use a
combinatorial construction viz.,
p A2 motif ðÞ ~p 2 incorrect order ðÞ |p two from 9 ðÞ
|p constrained at two locations ðÞ
~
1
2
|
1
36
|
207|8|6
209
~1:6667|10{3
The total number of A2 motifs in the coding region of the
genome will then be,
1:6667|10{3|3|107&50000
5. We now must find the number of motifs that are one mutation
away from being recognized as A2 motifs. For a motif to be one
mutation away from being recognized as A2, it must already
have a compatible residue in either the B or the F pocket and
an incompatible one in the other. Therefore, to find the
probable number of motifs one mutation away from A2, we use
a combinatorial construction as above to compute the
probability of each of these two exclusive cases individually
and then add them. This is calculated as,
p one from A2 ðÞ ~
1
72
|
207|12|6
209 z
207|8|14
209
  
~6:4|10{3
The total number of epitopes one mutation away from A2 will
then simply be,
6:4|10{3|3|107&191670
6. We know, from previous calculations the number of active
mutations in the coding region of the genome. Operating
under the assumption that these mutations occur randomly, we
can compute the average value for the number of such ‘false
positive’ incidences in the genome. This comes out to be,
90
3|107 |191670&:575:
Thus, we conclude that the total number of 9-mer motifs that
can mutate and be recognized as HLA A2 motifs is of the order
of 0.6 epitopes per cell, in a tumor that has arisen from 300
division cycles. (Parenthetically, these calculations assume that
the mutations are neutral with respect to their effects on
proteasome cleavage and transport of peptides through
transporters associated with antigen processing.) This number
will clearly increase as the tumor undergoes more cell cycles
Fig. 3(a). With a total of 6 MHC I alleles, and assuming that the
frequency of other alleles is similar to A2, there may be up to
3.6 total new tumor-specific MHC I epitopes per tumor cell at
this stage. The number of such epitopes shall clearly increase in
a tumor that is larger, or that has a higher mutation rate as a
result of genomic instability, or one that has undergone a larger
number of cycles for any reason,including a higher death rate
Fig. 3(b). Thus, in the not uncommon scenario of a tumor with
a hundred fold higher mutation rate, one may expect 360 new
tumor-specific MHC I epitopes per tumor cell. Clearly, the
actual number of new epitopes may be anywhere between 3.6
and 360 per cell depending upon the mutation rate. While this
manuscript was under preparation for submission, we became
aware of the study by Segal et al. [14] where the authors have
actually analyzed in silico the number of possible tumor-
specific HLA A201 epitopes based on known partial sequences
of tumor transcripts; they calculate individual breast and colon
cancers to have between 7 and 10 new epitopes. These
numbers are clearly consistent with our theoretical predictions.
Figure 2. Modeling the numbers of accumulating mutations in dividing cells as a function of rates of cell death using a probabilistic
model. Rate of cell death is defined as the fraction of cells dying in each generation. As an example, if a single cell divides into two, and only 1.6 of
these two cells survive, the death rate is denoted as 0.4. (a) Number of cell cycles required for a tumor to grow from a single cell to 10
9 cells (<1c m
3)
as a function of rates of cell death. The higher the death rates, the more times the cells have to divide to create the same size of tumor. Note on the
right vertical axis, that the number of accumulating mutations per cell also rises with the number of cell divisions undergone; the numbers are
plotted with an assumed mutation rate of 5610
29 per bp per cell division cycle. (b) The region of (a) denoting death rates between 0.8 and 1 is
magnified; death rates between 0.8 and 1 represent the most realistic scenario for a tumor growing in vivo. Note that the vertical axis is plotted on a
logarithmic scale.
doi:10.1371/journal.pone.0006094.g002
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Summary of results
Our study models the size of the repertoire of tumor-specific
MHC I epitopes in a tumor, starting from first principles of
genetics. We hasten to emphasize that the modeling here is
restricted to truly tumor-specific epitopes, that may not be present
in normal tissues. An extensive database that documents the
repertoire of MHC I epitopes that are shared between normal
tissues and tumors (such as differentiation antigens, cancer testes
antigens etc) exists [15,16], and is not the subject of this analysis.
Our analyses show that (a) each cell of a relatively small human
tumor of 1 cm
3 harbors approximately 900 individual mutations,
assuming a spontaneous mutation rate of 5610
29/bp/cell cycle. If
one factors in the presence of mutator mutations, or other
mechanisms of genetic instability, a proportionately higher
number of mutations is obtained. Corresponding numbers of
mutations can be derived for other mutation rates, higher and
lower. Accepting that a mutation must exist in at least 10% of the
cells in order to be detectable by DNA amplification methods, one
would detect *120 mutations per cell in this tumor at the basic
mutation rate. (b) If the modeling takes into account the fact that a
significant proportion of cancer cells die even as the cancer
progresses, the number of mutations in a tumor varies directly with
the death rate; the higher the death rate during the tumor’s
progression, the higher the number of mutations; (c) Translation of
the spontaneous mutations at the basic rate of 5610
29/bp/cell
cycle to the changes in amino acid composition of the proteome
suggests that a human tumor of 1 cm
3 shall harbor *4 new
tumor-specific epitopes per tumor cell. In a larger tumor, and in
tumors with higher mutation rates due to genetic instability, or
tumors with certain death rates, a substantially higher number of
new MHC I epitopes is generated, such that a clinically detectable
tumor may harbor hundreds of tumor-specific epitopes.
This model has a number of limitations. The number of all
potential A2 epitopes calculated is based on the assumption that
each of the possible twenty amino acids can occupy any position in
a protein. This is clearly not so, and corrections for this factor shall
alter the final numbers to a minor degree. Secondly, not all
potential epitopes may be generated due to constraints in
processing, the half life of proteins and other factors [17,18].
Hence, the number of actual as opposed to potential epitopes may
be as low as 10% of the modeled number. Conversely, the model
only considers point mutations, and thus ignores considerable
sources of additional genetic and hence immunogenic alterations.
These limitations, in either direction, should be borne in mind in
interpreting the physiological consequences of our model.
Comparison with previous results
Tomlinson et al. [6] have estimated 1250 mutations per
adenocarcinoma cell (in a cancer that has grown over 1000 cell
cycles), assuming a mutation rate of 5610
29 per bp per cell cycle.
The results of our calculations lead us to qualitatively similar
results. Our estimates are also generally consistent with the
number of 10,000 mutations per cell arrived at experimentally by
Stoler et al. [19] They are also concordant with the range of
frequency of ‘‘passenger’’ somatic mutations observed by Green-
man et al. in an array of cancer genomes [20]. Our model operates
at the level of probabilities of mutations at the level of single
nucleotides, as opposed to the geometric series used by Tomlinson
et al. The probabilistic approach, while harder to implement,
allows resolution of questions not addressable by the geometric
progression approach. The modeling of the size of the epitope
repertoire, as performed here, is one such question. No previous
study has modeled the number of new tumor-specific epitopes
generated as a result of tumor progression, and hence such a
comparison is not possible. However, a comment regarding the
estimates regarding the total number of A2 epitopes present in
normal proteome is instructive. We calculate as *50,000 the total
number of such epitopes. Intestingly, Assarson et al [17]. calculate
that the number of A2 epitopes in a 100 amino acid stretch of the
vaccinia virus genome to be about 2.5. If the total human
proteome consisting of 10
7 amino acids were to follow similar
rules, it may be expected to contain *250,000 A2 epitopes by
Figure 3. Modeling the numbers of accumulating tumor-specific HLA A2-restricted neo-epitopes in dividing human cancer cells
using a probabilistic model. (a) Prediction of average number of accumulated A2-restricted epitopes per cell as a function of numbers of cell
cycles. The model assumes a diploid DNA content of 6610
9 bp and a number of possible mutation rates (10
29,5610
29,10
28,5610
28 per bp per cell
cycle) as indicated. The higher mutation rates are more representative of human cancers. (b) The expected numbers of A2-restricted tumor-specific
neo-epitopes in tumors (<1c m
3 size) with varying inherent rates of cell death. The higher the death rate, the higher the number of cell cycles
required for a tumor to grow to a certain size (as shown in Fig. 2), and the higher the number of tumor-specific neo-epitopes. This figure assumes a
mutation rate of 5610
29 per bp per cell division in the tumor.
doi:10.1371/journal.pone.0006094.g003
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calculations is about 20 percent of that calculated by Assarson et
al., and thus significantly, but not qualitatively different. The most
pertinent calculations for us are those made by Segal et al [14];
these authors applied in silico-based epitope prediction algorithms
on 1152 peptides containing missense mutations in breast and
colorectal cancers and calculated that individual cancers have
between 7 and 10 new tumor-specific HLA 0201 epitopes. These
numbers are quite close to those arrived at in our calculations.
Testable predictions on molecular genetics of human
tumors
A number of predictions have been made regarding the
numbers of mutations in human cancers. While the human
genome of two human individuals has been sequenced, the
complete sequence of a human, or a murine tumor genome
remains to be determined. Considering the sliding costs of
sequencing, it is now well within the realm of possibility that
one or more tumor genomes shall be sequenced in short order.
Such an analysis, preferably carried out along with the non-tumor
genome of the same individual, shall be enormously informative
with respect to the models generated here and in other studies. It is
worth re-emphasizing here that our present model only considers
point mutations, and not the other more significant forms of
genetic modifications including chromosomal instability, deletions
etc. As such, our models present a minimal picture of the genetic
changes associated with carcinogenesis. The other aspect that is
implicit in our model is that of uniqueness of the genetic signature
of each individual cancer. As the mutations are assumed to be
random, the non-malignancy associated mutations, and these are
presumably the most of them, would be unique to each tumor.
This prediction shall also be put to test by the sequencing efforts.
Implications for immune responses to cancers
Our model has several novel implications. It suggests that a
growing tumor is not immunologically recognizable because at the
very early stages, it does not have any truly tumor-specific
immunogenic epitopes! In the simplest scenario in our model, a
tumor without genetic instability and without significant rates of
cell death may easily grow to a size of 1 cm
3 and may have only a
single immunogenic epitope, if that, at that stage. This provides a
perfect mechanism for tumors to grow un-detected under the
immunological radar. As they grow larger, they of course shall
become more immunogenic, and hence more visible. Very
interestingly, Gatenby et al [21]. have reached a similar conclusion
purely on information-theoretic grounds. They conclude that the
Fisher information of a tumor is very low in the early stages of its
growth, resulting in an error of at least 30% in the best possible
estimate of its time of origin. We find it gratifying that our
probabilistic treatment of nucleotide mutation predicts the same
result. With the time that it takes tumors to achieve larger sizes,
they shall also have had more opportunity to develop an immuno-
subversive armamentarium. The tumors that fail to develop such
immuno-evasive mechanisms, which indeed may be a substantial
proportion of them, possibly regress and are never detected
clinically. The phenomenon of regressor tumors in mice [22], the
increased incidence of cancers in immunologically suppressed
patients [23], and the recent evidence affirming the role of
immunological surveillance against tumors in mice [24], all
indicate that this might indeed be the case. The phenomena of
immune editing and immune evasion [25] must therefore be
considered central to development of malignancy.
Our model is consistent with the fact that a number of true
tumor-specific mutations have been identified in human and
mouse tumors, and that these are individually tumor-specific
[26,27,28,29,30,31,32,33,34,35,36,37,38,39]. In fact, in almost
every instance where immune response can be correlated to tumor
rejection, the immune response is directed to these true tumor-
specific mutations [26,31,33,34]. However, only a relatively small
number of individually specific mutations have been detected and
structurally defined. We suggest that at least two reasons for this
possible discrepancy; one, that the epitopes establish a hierarchy
such that only the dominant epitopes are identified. Assarson et al
[17]. estimate that 10 percent or fewer potential epitopes may be
detected for this reason. Secondly, the methodological logistics of
identifying epitopes of tumors are heavily biased towards detection
of shared, and not true tumor-specific epitopes.
Our results have an important bearing on the immunogenicity
of cancer stem cells. Regardless of the merits of the evidence
supporting their existence [40], our results suggest that cancer
stem cells shall harbor few mutations due to their asymmetric
proliferative properties, and hence shall be inherently poorly
immunogenic. They may also therefore be poorly responsive to
immunotherapy.
Implications for immunotherapy of human cancers
Our results suggest that human tumors of even clinically modest
sizes harbor significant numbers of true tumor-specific epitopes
generated as a result of the spontaneous mutations that are
inalienably associated with cell division. These tumor-specific
epitopes are predicted to be unique to each individual tumor
because of the randomness of the mutation process. These
considerations suggest a renewed emphasis on individualized
immunotherapy of human cancer. Preliminary positive results
from randomized Phase 3 clinical trials where autologous tumor-
derived heat shock protein-peptide vaccines - which are based on
the individually specific immunogenicity of cancers, are consistent
with our model [41,42]. The most extreme form of individuali-
zation of immunotherapy would of course consist of sequencing of
the entire genome of each patient’s tumor, followed by listing of
the unique tumor-specific epitopes and immunization against a
panel of such epitopes [43]. Our modeling predicts that the
number of such epitopes shall not be inordinately large. With the
rapid and continuing decline in the cost of sequencing, such
approaches are not beyond the bounds of possibility in the near
future. Further, considering that tumors already harbor a
substantial immunogenic repertoire, a renewed effort towards
dis-inhibition of immune responses, such as through blocking
antibodies to CTLA4 [31,44] or other such molecules, or through
disruption of T regulatory networks [45], in combination with
individualized vacci-therapy, may offer the best chance of success.
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